Is Berubicin effective?
Berubicin is an anthracycline, a class of anticancer agents that are among the most powerful chemotherapy drugs and effective against more types of cancer than any other class of chemotherapeutic agents.
Is Berubicin FDA approved?
In June 11, 2020, the FDA granted berubicin an orphan drug designation for the treatment of patients with malignant gliomas.
What cancers is Avastin used for?
Avastin is FDA-approved to treat colon cancer. This condition is also called colorectal cancer or bowel cancer. Specifically, Avastin is approved to treat metastatic colon cancer. With metastatic colon cancer, the cancer has spread out of your colon into other parts of your body.
Is Avastin chemotherapy or immunotherapy?
Avastin ® (bevacizumab) works differently than chemotherapy. Avastin is used with chemotherapy and hits your cancer from another angle. Avastin is a tumor-starving (anti-angiogenic) therapy. The purpose of Avastin is to prevent the growth of new blood vessels.
Does Avastin shrink tumors?
Avastin helps prevent blood vessels from reaching the tumor; this could starve the tumor. However, in a study of mCRC patients who continued on Avastin for second-line treatment after a first-line treatment that included Avastin, tumors did not shrink.
What happens when you stop taking Avastin?
If you stop Avastin, you should keep using birth control for 6 months before trying to become pregnant. Planning to become pregnant. Taking Avastin could cause a woman’s ovaries to stop working and may impair her ability to have children. Breastfeeding.
How can I learn more about the berubicin study?
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor. Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04762069 Study data will be shared with WPD Pharmaceuticals, Inc., sub-licensee of Berubicin.
Does berubicin have fast track FDA designation?
“Receiving Fast Track Designation from the U.S. FDA is a huge achievement in our advancement of berubicin for the treatment of glioblastoma, the most aggressive, deadly and treatment-resistant type of cancer that forms in the brain.
Is berubicin an effective monotherapy for recurrent glioblastoma multiforme?
The novel anthracycline agent Berubicin appears to have a toxicity profile consistent with that of other anthracyclines and demonstrates exceptional activity as monotherapy for recurrent glioblastoma multiforme.
Does berubicin cause DLT?
The most common DLT was myelosuppression, specifically neutropenia. The MTD of Berubicin was determined to be 7.5 mg/m 2 /day. At that dose, one of five patients experienced a DLT, while two of six patients experienced a DLT at the next higher dose, 9.6 mg/m 2 /day.
https://www.youtube.com/watch?v=paMh6DWpkrc
